Antiphospholipid Antibodies and the Antiphospholipid Syndrome: From Coagulation to the Clinic.

J. Abdulrehman,R. Selby

DOI: https://doi.org/10.1093/jalm/jfab134

2022-01-05

The Journal of Applied Laboratory Medicine

Abstract:Antiphospholipid syndrome (APS) is a systemic, autoimmune disorder characterized by the pres-ence of antiphospholipid antibodies (APLA) di-rected to various plasma proteins bound to anionic phospholipids. The clinical syndrome of APS is variable, resulting commonly in venous or arterial thrombosis and/or pregnancy morbidity and is defined by clinical and laboratory consensus criteria (1). “Noncriteria” clinical presentations and severe presentations such as catastrophic APS (a syndrome of multiorgan failure) are less common. Both criteria and noncriteria presentations are described in Table 1. APS patients may have under-lying systemic lupus erythematosus, but approxi-mately half of the patients do not and are diagnosed as primary APS (2). Although asymptom-atic carriers of APLA are identified, the true preva-lence in the general population is unknown, due to the absence of large population-based studies. In symptomatic patients, it is estimated that APLA may be detected in up to 10% of cases of stroke, venous thrombosis, and pregnancy morbidity (3) and in 17% of patients less than 50 years with stroke (4), with an estimated incidence of 1 to 2 persons per 100 000 population (5).

Medicine